According to TCGA data, SETDB1 is amplified in 10.8% of liver cancers, 9.1% of breast cancers, 8.4% of bladder cancers, 7.4% of ovarian cancers, and 6% of uterine cancers, and mutated in about 5% of melanomas. The gene discussed is SETDB1; the disease is melanoma.